Guidelines for respiratory syncytial virus prophylaxis. An update;Recomendaciones para la prevención de la infección por virus respiratorio sincitial: Revisión

Anales Espanoles de Pediatria

Volumn 56, Issue 4, 2002, Pages 334-336

  Carbonell Estrany, X ^a   Quero Jimenez J ^a  

^a NONE   (Spain)

Author keywords

Bronchiolitis; Hospitalization; Monoclonal antibodies; Palivizumab; Premature infants; Respiratory syncytial virus

Indexed keywords

MONOCLONAL ANTIBODY; PALIVIZUMAB;

BRONCHIOLITIS; DRUG EFFICACY; HOSPITALIZATION; HUMAN; INFANT; INFECTION PREVENTION; PRACTICE GUIDELINE; PREMATURITY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SHORT SURVEY; VIRUS INFECTION;

AGE FACTORS; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BRONCHIOLITIS; COHORT STUDIES; GESTATIONAL AGE; HOSPITALIZATION; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; INTENSIVE CARE UNITS, NEONATAL; PRACTICE GUIDELINES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SPAIN;

EID: 0036327163     PISSN: 03024342     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (14)

1. Recomendaciones para la prevención de la infección por virus respiratorio sincitial
2. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: A prospective study
3. Hospitalization rates for respiratory syncytial virus infection in premature infants younger born during two consecutive seasons
4. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
5. Effectiveness of palivizumab: Evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season
6. Effectiveness of palivizumab for preventing serious RSV disease
7. Prophylaxis for respiratory syncytial virus in Canada: Outcomes and utilization with palivizumab during the 1999-2000 season
8. Palivizumab surveillance: An evaluation of the RSV-related hospitalizations of high-risk children after palivizumab prophylaxis in the Netherlands during the 1999-2000 season
9. Prophylaxis for Respiratory syncytial virus
10. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children
11. Respiratory syncytial virus and premature infants born at 32 weeks gestation or earlier
12. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection
13. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis